TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24907225

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg once daily) plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (total treatment duration 24 or 48 weeks based on response)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (total treatment duration 48 weeks)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Simeprevir group
Number of subjects: 394
Study: 22996850

Group type: EXPERIMENTAL
Intervention: 10 weeks of specific resistance training for the neck/shoulder muscles for 2 minutes per day 5 times a week
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 10 weeks of specific resistance training for the neck/shoulder muscles for 12 minutes per day 5 times a week
Number of subjects: 198

Group type: COMPARATOR
Intervention: Weekly information on general health (control group)
Number of subjects: 198
Study: 20297703

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluoride varnish (F‐varnish)
Number of subjects: 6
Study: 17300719

Group type: EXPERIMENTAL
Intervention: Artemisinin compounds
Number of subjects: 945
Study: 15604592

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.02% for 3 min)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intraoperative doxorubicin (0.02% for 3 min)
Number of subjects: 56
Study: 12871538

Group type: EXPERIMENTAL
Intervention: Oral ximelagatran (24, 36, 48 or 60 mg twice daily)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Oral ximelagatran
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Oral ximelagatran and Low‐molecular‐weight heparin (dalteparin) followed by warfarin
Number of subjects: 350
Study: 10357864

Group type: EXPERIMENTAL
Intervention: 2% butenafine hydrochloride and 5% Melaleuca alternifolia oil in cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8542165

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-dose and high-dose inhaled terbutaline
Number of subjects: 30
Study: 1792931

Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 167

Group type: COMPARATOR
Intervention: 150 mg clomipramine
Number of subjects: 167

Group type: COMPARATOR
Intervention: 30 mg isocarboxazide
Number of subjects: 167
Study: 6359972

Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl combination (0.5% bupivacaine 1.06 ml per metamer + fentanyl 1.70 +/- 0.09 micrograms X kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bupivacaine alone (0.5% bupivacaine 1.18 ml per metamer)
Number of subjects: 30
Study: 30712198

Group type: EXPERIMENTAL
Intervention: Self-administered complex decongestive therapy (saCDT) course
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care (CTRL)
Number of subjects: 41
Study: 30402575

Group type: EXPERIMENTAL
Intervention: Scrotal incision hydrocelectomy
Number of subjects: 156

Group type: COMPARATOR
Intervention: Traditional inguinal incision hydrocelectomy
Number of subjects: 156
Study: 27207001

Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the most common injection site with 3% mepivacaine solution
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the anterior injection site with 3% mepivacaine solution
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: AMSA nerve block injection at the posterior injection site with 3% mepivacaine solution
Number of subjects: 47
Study: 25377582

Group type: EXPERIMENTAL
Intervention: Fibrinogen/thrombin‐coated collagen patch as wound dressing
Number of subjects: 27
Study: 22430233

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-enhanced cardiopulmonary resuscitation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside-enhanced cardiopulmonary resuscitation + adenosine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Controlled pauses - sodium nitroprusside-enhanced cardiopulmonary resuscitation + adenosine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard cardiopulmonary resuscitation
Number of subjects: 32
Study: 20449526

Group type: EXPERIMENTAL
Intervention: Speech therapy combined with beclomethasone diproprionate through exclusively nasal inhalation (BDT group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Only beclomethasone diproprionate through exclusively nasal inhalation (BDI group)
Number of subjects: 24
Study: 17660157

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no lipid‐lowering medication)
Number of subjects: 93
Study: 15642054

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) in treated patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 20
Study: 12145597

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 10199766

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate with progressive resistance training (PRT)
Number of subjects: 30
Study: 7755068

Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times a day)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 938
Study: 2271752

Group type: EXPERIMENTAL
Intervention: URO-TS D
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bactrim F
Number of subjects: 10
Study: 436200

Group type: EXPERIMENTAL
Intervention: Hydralazine (100 mg) and Isosorbide Dinitrate (40 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30262449

Group type: EXPERIMENTAL
Intervention: Mobile app use for managing depressive symptoms
Number of subjects: 16
Study: 27023860

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 209

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 209
Study: 25549816

Group type: EXPERIMENTAL
Intervention: CO2 laser followed by 5FU (group III)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 5FU (group I)
Number of subjects: 68

Group type: COMPARATOR
Intervention: CO2 laser (group II)
Number of subjects: 68
Study: 23765173

Group type: EXPERIMENTAL
Intervention: RTUS-guided PICC placement
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard radiograph placement
Number of subjects: 48
Study: 20509084

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 0
Study: 18346063

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment with 5-minute application of liposomal lidocaine cream
Number of subjects: 70

Group type: COMPARATOR
Intervention: 30-minute application of liposomal lidocaine cream (Control)
Number of subjects: 70
Study: 16010505

Group type: EXPERIMENTAL
Intervention: Celiac plexus block
Number of subjects: 55
Study: 14667877

Group type: EXPERIMENTAL
Intervention: Modified ICSI with morphologically selected spermatozoa
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine ICSI
Number of subjects: 62
Study: 10809240

Group type: EXPERIMENTAL
Intervention: Icodextrin (Ico)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Glucose (Glu)
Number of subjects: 38
Study: 8866584

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide, 80 microg q.i.d. for 14 days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1509526

Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 64
Study: 6189335

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate (active corticosteroid preparation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (basal formulation only)
Number of subjects: 18
Study: 31752774

Group type: EXPERIMENTAL
Intervention: Text 4 change SMS intervention group
Number of subjects: 1016

Group type: COMPARATOR
Intervention: Control group receiving group education about lifestyle modifications and written information about diet and physical activity
Number of subjects: 1016
Study: 29458319

Group type: EXPERIMENTAL
Intervention: PAV+
Number of subjects: 50

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 50
Study: 27367818

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 21004

Group type: COMPARATOR
Intervention: chlorthalidone
Number of subjects: 21004

Group type: EXPERIMENTAL
Intervention: amlodipine
Number of subjects: 21004

Group type: EXPERIMENTAL
Intervention: pravastatin
Number of subjects: 21004
Study: 24599197

Group type: EXPERIMENTAL
Intervention: Patient-specific instruments
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard instruments
Number of subjects: 47
Study: 22901620

Group type: EXPERIMENTAL
Intervention: Alternate-week dexamethasone (10 mg/m² per day on days 0-6 and 14-20)
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Continuous dexamethasone (10 mg/m² per day on days 0-20)
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Alternate-week dexamethasone
Number of subjects: 2056

Group type: COMPARATOR
Intervention: Continuous dexamethasone
Number of subjects: 2056
Study: 20695801

Group type: EXPERIMENTAL
Intervention: Ceftaroline (600 mg every 12 h)
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam (1 g each every 12 h)
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Ceftaroline
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam
Number of subjects: 1378

Group type: EXPERIMENTAL
Intervention: Ceftaroline and Vancomycin plus aztreonam
Number of subjects: 1378
Study: 18234046

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 15737951

Group type: EXPERIMENTAL
Intervention: Filgrastim (300-480 microg subcutaneously for up to seven days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 12506171

Group type: EXPERIMENTAL
Intervention: FU/LV + low‐dose bevacizumab (5 mg/kg every 2 weeks)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: FU/LV + high‐dose bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 104

Group type: COMPARATOR
Intervention: FU/LV alone
Number of subjects: 104
Study: 11758301

Group type: EXPERIMENTAL
Intervention: Active intervention (inspections, information distribution, sanctions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular intervention (inspections, information distribution, sanctions)
Number of subjects: 0
Study: 9236418

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 i.u./kg, twice-daily subcutaneous injections)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Unfractionated heparin (dose-adjusted intravenous infusion)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Dalteparin (7500 i.u. once daily, subcutaneous)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1482
Study: 8137694

Group type: EXPERIMENTAL
Intervention: Enhanced preparation intervention (written instructions, reminder to post instructions in the bathroom, toilet seat cover with reminder, nurse-initiated telephone call)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard preparation intervention (written instructions, telephone number for questions)
Number of subjects: 179
Study: 3627588

Group type: EXPERIMENTAL
Intervention: 16 dimethyl prostaglandin E2 (PGE2) vaginal suppository
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 4-mm hypan plastic dilator
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: small Laminaria japonica tent
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study: 30734090

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30500646

Group type: EXPERIMENTAL
Intervention: TeleHealth Electronic Monitoring (THEM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard Of Care (SOC)
Number of subjects: 30
Study: 28600373

Group type: EXPERIMENTAL
Intervention: Physiatrist-directed prehabilitation intervention including assessment and supervised exercise programme.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with no prehabilitation interventions.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physiatrist-directed prehabilitation intervention.
Number of subjects: 40
Study: 25087085

Group type: EXPERIMENTAL
Intervention: Continuous furosemide infusion (cIV)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Bolus injections of furosemide (iIV)
Number of subjects: 57
Study: 23166062

Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Professional education (control)
Number of subjects: 100
Study: 24956430

Group type: EXPERIMENTAL
Intervention: Roots of Empathy (ROE) program
Number of subjects: 445

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 445
Study: 19231632

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg (dose increase for patients with platelet counts <50,000 after 3 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 114
Study: 16707863

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding ICD to CRT
Number of subjects: 0
Study: 14643092

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11103365

Group type: EXPERIMENTAL
Intervention: Interviewed in Turkish language
Number of subjects: 141

Group type: COMPARATOR
Intervention: Interviewed in German language
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Turkish patients with good German language knowledge
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Turkish patients
Number of subjects: 141
Study: 9059091

Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 fentanyl
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 15 micrograms.kg‐1 fentanyl
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (inhalational anaesthesia without fentanyl)
Number of subjects: 16
Study: 8345609

Group type: EXPERIMENTAL
Intervention: Immunostimulating bacterial extract
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 30673055

Group type: EXPERIMENTAL
Intervention: Personality evaluation using the Caliper Profile Questionnaire
Number of subjects: 40
Study: 30060980

Group type: EXPERIMENTAL
Intervention: Pre-existing GA (without neovascular AMD)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Incident GA
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: GA enlargement rate in pre-existing GA
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: GA enlargement rate in incident GA
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Combined group GA enlargement
Number of subjects: 411

Group type: COMPARATOR
Intervention: AREDS2 treatment assignment
Number of subjects: 411

Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: ARMS2 risk genotype
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: C3 non-risk genotype
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: APOE non-risk genotype
Number of subjects: 411
Study: 27486544

Group type: EXPERIMENTAL
Intervention: Vilazodone (2,040 mg/d)
Number of subjects: 1462
Study: 25146745

Group type: EXPERIMENTAL
Intervention: Ribavirin aerosol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 22006541

Group type: EXPERIMENTAL
Intervention: 40 mg GS-9450
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 10 mg GS-9450
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: GS-9450 treatment groups
Number of subjects: 124
Study: 20209171

Group type: EXPERIMENTAL
Intervention: RMGIC only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RMGIC and corresponding primer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RMGIC, acid etching, and Scotchbond Multipurpose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RMGIC and two‐step self‐etching primer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RMGIC and one‐step primer
Number of subjects: 45
Study: 17109733

Group type: EXPERIMENTAL
Intervention: Daclizumab (single-dose administration)
Number of subjects: 0
Study: 15800130

Group type: EXPERIMENTAL
Intervention: AA plus G dialysate (Nutrineal 1.1%, 27 g of AA and Physioneal 1.36 to 3.86%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control dialysate (G)
Number of subjects: 8
Study: 12468113

Group type: EXPERIMENTAL
Intervention: GHRH administered intravenously (50 microg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRH administered intranasally (300 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CRH/vasopressin stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRH (both routes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: i.v. GHRH application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: intranasal GHRH administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood pressure and heart rate measurements
Number of subjects: 20
Study: 10199532

Group type: EXPERIMENTAL
Intervention: Increased minute ventilation (VE) by +35%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reduced minute ventilation (VE) by -35%
Number of subjects: 20
Study: 7775727

Group type: EXPERIMENTAL
Intervention: 24 g psyllium fiber daily for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo fiber daily for 1 month
Number of subjects: 10
Study: 2187266

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study: 400867

Group type: EXPERIMENTAL
Intervention: Betamimetic drug administered to the mother from week 33 to 35
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31645291

Group type: EXPERIMENTAL
Intervention: Community-based interventions for dengue prevention
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Outreach activities (video/debate sessions, school and home education sessions, focus groups)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Community working groups for identifying and eliminating mosquito breeding sites
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Preventive text messages to residents
Number of subjects: 983
Study: 28916479

Group type: EXPERIMENTAL
Intervention: Dietary nitrate (NO3‐) ingestion via beetroot juice containing 11.2 mmol of NO3‐
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (beetroot juice devoid of NO3‐)
Number of subjects: 8
Study: 27074186

Group type: EXPERIMENTAL
Intervention: Auditory Training (AT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Visual Training (Control)
Number of subjects: 12
Study: 25209523

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% cream, applied twice daily for 4 days (every 12 h) with a single dose on day 1 and a final single dose on day 6.
Number of subjects: 46
Study: 22310296

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oseltamivir (early initiation within 48 hours)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Oseltamivir (for influenza B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 300
Study: 20207062

Group type: EXPERIMENTAL
Intervention: IN ketorolac 31.5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: IN placebo
Number of subjects: 80
Study: 17977171

Group type: EXPERIMENTAL
Intervention: Slow-release dinoprostone vaginal insert (VI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 0.5‐mg dinoprostone intracervical (IC) gel
Number of subjects: 100
Study: 16411386

Group type: EXPERIMENTAL
Intervention: Plasma-derived protein C zymogen concentrate (Ceprotin®, Baxter) (150 U/kg as a slow bolus infusion followed by 30 U/kg/h continuous infusion until 4 hours after LPS-infusion)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Plasma-derived protein C zymogen concentrate (Ceprotin®, Baxter)
Number of subjects: 11
Study: 12473152

Group type: EXPERIMENTAL
Intervention: Self-educating transfusion request form
Number of subjects: 56171

Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 56171
Study: 9824121

Group type: EXPERIMENTAL
Intervention: Diabetics with constipation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constipated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 0
Study: 7657130

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice a day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 2663681

Group type: EXPERIMENTAL
Intervention: Tilidin/naloxone (Valoron N; VAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tramadol (TRA)
Number of subjects: 0
Study: 934534

Group type: EXPERIMENTAL
Intervention: Reserpine (0.20 mg administered intravenously in standardized cycles of twenty administrations)
Number of subjects: 300
Study: 30942385

Group type: EXPERIMENTAL
Intervention: Individualized Music
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Melomics-Health Listening
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Music (Control)
Number of subjects: 45
Study: 31192968

Group type: EXPERIMENTAL
Intervention: Conventional laser treatment
Number of subjects: 39

Group type: COMPARATOR
Intervention: PASCAL treatment
Number of subjects: 39
Study: 28202037

Group type: EXPERIMENTAL
Intervention: Tailored multifaceted intervention over a 6 month trial period
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300